MedTrace Logo

Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

NCT03309592 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-12-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the combination of ambrisentan and tadalafil in reducing mPAP to below 35mmHg in patients with moderate to severe Portopulmonary Hypertension (POPH) as a means to candidacy for liver transplantation.

Conditions

  • Portopulmonary Hypertension
  • Pulmonary Hypertension
  • Cirrhosis, Liver

Interventions

DRUG

Ambrisentan Pill

Will be administered as stated in Arm/Group Descriptions

DRUG

Tadalafil Pill

Will be administered as stated in Arm/Group Descriptions

Sponsors & Collaborators

Principal Investigators

  • Stacy Mandras, MD · Director, Pulmonary Hypertension

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-12
Primary Completion
2018-11-01
Completion
2018-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03309592 on ClinicalTrials.gov